US20030186454A1 - Apparatus and method for lead profiling assay - Google Patents
Apparatus and method for lead profiling assay Download PDFInfo
- Publication number
- US20030186454A1 US20030186454A1 US10/303,446 US30344602A US2003186454A1 US 20030186454 A1 US20030186454 A1 US 20030186454A1 US 30344602 A US30344602 A US 30344602A US 2003186454 A1 US2003186454 A1 US 2003186454A1
- Authority
- US
- United States
- Prior art keywords
- less
- drug discovery
- drug
- profiling assays
- discovery according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 238000003556 assay Methods 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 238000012360 testing method Methods 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 238000007876 drug discovery Methods 0.000 claims abstract description 23
- 238000000151 deposition Methods 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 239000000126 substance Substances 0.000 claims description 15
- 238000005259 measurement Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 description 65
- 230000027455 binding Effects 0.000 description 15
- 238000009739 binding Methods 0.000 description 15
- 239000003550 marker Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000013537 high throughput screening Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- 150000002611 lead compounds Chemical class 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 238000007707 calorimetry Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000005842 biochemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002875 fluorescence polarization Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 108091007999 druggable proteins Proteins 0.000 description 2
- 102000038037 druggable proteins Human genes 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008646 thermal stress Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
- G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
- G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
- G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
- G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
- G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
- Y10S977/953—Detector using nanostructure
- Y10S977/957—Of chemical property or presence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25625—Dilution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2575—Volumetric liquid transfer
Definitions
- This invention relates generally to a method for performing assays for drug discovery, and more specifically, to a method for performing lead drug profiling assays.
- the sample to be studied is precious, and it might not be acceptable to use the relatively large amount of material required by a standard microcalorimeter to perform only one measurement.
- a standard microcalorimeter such as those sold, for example, by MicroCal® Inc. (model VP-ITC) or Calorimetry Sciences Corporation® (model CSC-4500)
- Performing a measurement in standard microcalorimeters, such as those sold, for example, by MicroCal® Inc. (model VP-ITC) or Calorimetry Sciences Corporation® (model CSC-4500) requires about 1 ml of sample, which means that one would possibly be faced with using a majority or all of the precious material for one or a small series of measurements. Tools that enable calorimetric measurements with much smaller sample sizes would be helpful in overcoming this limitation.
- a combinatorial library is a collection of chemical compounds which have been generated, by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” as reagents.
- a combinatorial polypeptide library is formed by combining a set of amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can theoretically be synthesized through such combinatorial mixing of chemical building blocks.
- a library Once a library has been constructed, it must be screened to identify compounds, which possess some kind of biological or pharmacological activity. For example, screening can be done with a specific biological compound, often referred to as a target that participates in a known biological pathway or is involved in some regulatory function.
- the library compounds that are found to react with the targets are candidates for affecting the biological activity of the target, and hence a candidate for a therapeutic agent.
- HTS high throughput screening
- a variety of measurement approaches has been used to screen combinatorial libraries for lead compounds, one of which is the competitive binding assay.
- a ligand often the natural ligand in a biological pathway, is identified that will bind well with the target protein molecule.
- the assay often requires the chemical attachment of a fluorescent molecule to this marker ligand such that the fluorescent molecule does not affect the manner in which the marker ligand reacts with the target protein.
- the ligand could be radioactively labeled or labeled with a chemiluminescent molecule.
- the target protein is exposed to a mixture of the test ligands and marker ligands often in microtitre wells.
- the wells are rinsed such that free marker ligand is washed away.
- the test ligand has blocked the active site of the target protein so the marker ligand cannot react and is washed away, while in cells where the target protein and test ligand have not reacted, the marker ligand has bound to the target protein and is not washed away.
- the competitive binding assay requires time and expense to develop the labeled reagents and assay.
- the principal components that need development are discovering a marker ligand and attaching a fluorophore to the marker in a manner that does not affect its reaction with the target protein. Attaching the fluorescent marker can often take 3 months of development or more and cost $250 k or more once the marker ligand is identified.
- a differential calorimeter that includes sample and reference cells, a thermal shield surrounding the cells, heating devices thermally coupled to the thermal shield and the cells, a temperature monitoring system, and a control system.
- the temperature monitoring system monitors the temperature of the shield, cell temperatures, and temperature differentials between the cells and the shield.
- the control system generates output signals for control of the heating devices, with a gain setting and scan rate selected by means of a user interface.
- Output control signals are functions of input temperature signals and the user-selected gain setting, as well as functions of input temperature signals and the user-selected scan rate using a mapping function stored in memory.
- CMOS complementary metal-oxide-semiconductor
- the chip fabricated using standard CMOS processes, includes a reference zone and a sample zone.
- the reference and sample zones may be at opposite ends of a suspended platform or may reside on separate platforms.
- Each zone is heated with an integrated polysilicon heater.
- a thermopile consisting of a succession of thermocouple junctions generates a voltage representing the temperature difference between the reference and sample zones.
- a calorimeter sensor apparatus utilizes microcantilevered spring elements for detecting thermal changes within a sample containing biomolecules which undergo chemical and biochemical reactions.
- the spring element includes a bimaterial layer of chemicals on a coated region on at least one surface of the microcantilever.
- the chemicals generate a differential thermal stress across the surface upon reaction of the chemicals with an analyte or biomolecules within the sample due to the heat of chemical reactions in the sample placed on the coated region.
- the thermal stress across the spring element surface creates mechanical bending of the microcantilever.
- the spring element has a low thermal mass to allow detection and measuring of heat transfers associated with chemical and biochemical reactions within a sample place on or near the coated region. Deflections of the cantilever are detected by a variety of detection techniques.
- a microcalorimeter in Lieberman, U.S. Pat. No. 6,193,413 (“System and Method for an Improved Calorimeter for Determining Thermodynamic Properties of Chemical and Biological Reactions”) includes a thin amorphous membrane anchored to a frame within an environmental chamber. Thermometers and heaters are placed on one side of a thermal conduction layer mounted on the central portion of the membrane. Samples are placed on two such membranes; each sample is heated and its individual heat capacity determined. The samples are then mixed by sandwiching the two microcalorimeters together to cause a binding reaction to occur. The amount of heat liberated during the reaction is measured to determine the enthalpy of binding.
- a method for performing drug lead profiling assays for drug discovery utilizing a nanocalorimeter includes depositing not less than one drop containing a target solution to be screened and not less than one drop containing a drug library compound on a test substrate. After the drops are merged, a determination is made as to whether a reaction has occurred.
- FIG. 1 is a flow chart illustrating a prior art method for performing drug lead profiling
- FIG. 2 is an embodiment of the method for performing lead profiling assays in accordance with the present invention.
- ligand refers to an agent that binds a target molecule.
- a ligand is not limited to an agent that binds a recognized functional region of the target protein e.g. the active site of an enzyme, the antigen-combining site of an antibody, the hormone-binding site of a receptor, a cofactor-binding site, and the like.
- a ligand can also be an agent that binds any surface or conformational domains of the target protein. Therefore, the ligands of the present invention encompass agents that in and of themselves may have no apparent or known biological function, beyond their ability to bind to the target protein in the manner described above.
- test ligand refers to an agent, comprising a compound, molecule or complex, which is being tested for its ability to bind to a target molecule.
- Test ligands can be virtually any agent, including without limitation metals, peptides, proteins, lipids, polysaccharides, nucleic acids, small organic molecules, and combinations thereof.
- Complex mixtures of substances such as natural product extracts, which may include more than one test ligand, can also be tested, and the component that binds the target molecule can be purified from the mixture in a subsequent step.
- target protein refers to a peptide, protein or protein complex for which identification of a ligand or binding partner is desired.
- Target proteins include without limitation peptides or proteins known or believed to be involved in the etiology of a given disease, condition or pathophysiological state, or in the regulation of physiological function.
- Target proteins may be derived from any living organism, such as a vertebrate, particularly a mammal and even more particularly a human. For use in the present invention, it is not necessary that the protein's biochemical function be specifically identified.
- Target proteins include without limitation receptors, enzymes, oncogene products, tumor suppressor gene products, vital proteins, and transcription factors, either in purified form or as part of a complex mixture of proteins and other compounds.
- target proteins may comprise wild type proteins, or, alternatively, mutant or variant proteins, including those with altered stability, activity, or other variant properties, or hybrid proteins to which foreign amino acid sequences, e.g. sequences that facilitate purification, have been added.
- test combination refers to the combination of a test ligand and a target protein.
- Control combination refers to the target protein in the absence of a test ligand.
- screening refers to the testing of a multiplicity of molecules or compounds for their ability to bind to a target molecule.
- the term “lead molecule” refers to a molecule or compound, from a combinatorial library or other collection, which displays relatively high affinity for a target molecule. High affinity is detected by this invention through the heat released in a chemical reaction.
- the terms “lead compound” and “lead molecule” are synonymous.
- target molecule encompasses peptides, proteins, nucleic-acids, protein-nucleic acid complexes and other receptors.
- the term encompasses both enzymes and proteins which are not enzymes.
- the term encompasses monomeric and multimeric proteins. Multimeric proteins may be homomeric or heteromeric.
- the term encompasses nucleic acids comprising at least two nucleotides, such as oligonucleotides. Nucleic acids can be single-stranded, double-stranded, or triple-stranded.
- the term encompasses a nucleic acid which is a synthetic oligonucleotide, a portion of a recombinant DNA molecule, or a portion of chromosomal DNA.
- target molecule also encompasses portions of peptides, secondary, tertiary, or quaternary structure through folding, with substituents including, but not limited to, cofactors, coenzymes, prosthetic groups, lipids, oligosaccharides, or phosphate groups.
- molecule refers to the compound, which is tested for binding affinity for the target molecule. This term encompasses chemical compounds of any structure, including, but not limited to nucleic acids and peptides. More specifically, the term “molecule” encompasses compounds in a compound or a combinatorial library. The terms “molecule” and “ligand” are synonymous.
- thermo change encompasses the release of energy in the form of heat or the absorption of energy in the form of heat.
- contacting a target molecule refers broadly to placing the target molecule in solution with the molecule to be screened for binding. Less broadly, contacting refers to the turning, swirling, shaking or vibrating of a solution of the target molecule and the molecule to be screened for binding. More specifically, contacting refers to the mixing of the target molecule with the molecule to be tested for binding. Mixing can be accomplished, for example, by repeated uptake and discharge through a pipette tip or by deposition by robotic means. Preferably, contacting refers to the equilibration of binding between the target molecule and the molecule to be tested for binding.
- biochemical conditions encompasses any component, thermodynamic property, or kinetic property of a physical, chemical, or biochemical reaction. Specifically, the term refers to conditions of temperature, pressure, protein concentration, pH, ionic strength, salt concentration, time, electric current, potential difference, and concentrations of cofactor, coenzyme, oxidizing agents, reducing agents, detergents, metal ion, ligands, buffer components, co-solvents including DMSO (dimethyl sulfoxide), glycerol, and related compounds, enhancers, and inhibitors.
- DMSO dimethyl sulfoxide
- glycerol glycerol
- lead profiling assay encompasses the testing for reaction of a compound or a series of compounds with known binding activity towards a desired target against a plurality of other targets so as to determine a reactivity profile for said compound of compounds.
- the present invention encompasses nanocalorimeters and nanocalorimeter arrays that enable measurement of enthalpic changes, such as enthalpic changes arising from reactions, phase changes, changes in molecular conformation, and the like. Furthermore, the present invention encompasses combinatorial methods and high-throughput screening methods that use nanocalorimeters in the study, discovery, and development of new compounds, materials, chemistries, and chemical processes, as well as high-throughput monitoring of compounds or materials, or high-throughput monitoring of the processes used to synthesize or modify compounds or materials. The present invention also relates to compounds or materials identified by the above methods and their therapeutic uses (for diagnostic, preventive or treatment purposes), uses in purification and separation methods, and uses related to their novel physical or chemical properties. For the purposes herein, a nanocalorimeter refers to a device capable of measuring heats of reaction in the range of nanocalories.
- the present invention encompasses high-throughput screening methods for identifying a ligand that binds a target protein. If the target protein to which the test ligand binds is associated with or causative of a disease or condition, the ligand may be useful for diagnosing, preventing or treating the disease or condition.
- a ligand identified by the present method can also be one that is used in a purification or separation method, such as a method that results in purification or separation of the target protein from a mixture.
- the present invention also relates to ligands identified by the present method and their therapeutic uses (for diagnostic, preventive or treatment purposes) and uses in purification and separation methods.
- the test ligand is combined with a target molecule, and the mixture is maintained under appropriate conditions and for a sufficient time to allow binding of the test ligand to the target molecule.
- Experimental conditions are determined empirically for each target molecule. When testing multiple test ligands, incubation conditions are usually chosen so that most ligand:target molecule interactions would be expected to proceed to completion. In high-throughput screening applications, the test ligand is usually present in molar excess relative to the target molecule.
- the target molecule can be in a soluble form, or, alternatively, can be bound to a solid phase matrix.
- the matrix may comprise without limitation beads, membrane filters, plastic surfaces, or other suitable solid supports.
- Binding to a given target is a prerequisite for pharmaceuticals intended to modify directly the action of that target.
- a test ligand may indicate the potential ability of the test ligand to alter target function and to be an effective pharmaceutical or lead compound for the development of such a pharmaceutical.
- the ligand may serve as the basis for the construction of hybrid compounds containing an additional component that has the potential to alter the target's function.
- a known compound that inhibits the activity of a family of related enzymes may be rendered specific to one member of the family by conjugation of the known compound to a ligand, identified by the methods of the present invention, that binds specifically to that member at a different site than that recognized by the known compound.
- the present method is based on physicochemical properties common to most targets gives it widespread application.
- the present invention can be applied to large-scale systematic high-throughput procedures that allow a cost-effective screening of many thousands of test ligands. Once a ligand has been identified by the methods of the present invention, it can be further analyzed in more detail using known methods specific to the particular target used. Also, the ligand can be tested for its ability to influence, either positively or negatively, a known biological activity of the target.
- a drug target protein is screened for reactivity against a large number (500,000) of compounds from a drug library of compounds. Often it is desirable to screen several different drug target proteins against the same library of proteins if the target proteins are thought to have a similar function such as the enzymatic function of a kinase.
- FIG. 1 there is shown an embodiment of a conventional drug screening process, a competitive screen, using a fluorescent assay.
- the reaction of the drug library compound with the target protein prevents the reaction of a second known reactive compound that contains a detectable label such as, in the case of a fluorescent assay, a fluorescent label.
- the level of reactivity of the drug library compound is inferred by detecting the fluorescence coming from the bound labeled compound.
- fluorescent assays are currently utilized in the art, but the two most practiced are fluorescence intensity and fluorescence polarization.
- a labeled ligand 1130 at a low concentration and one or more drug library compounds 1150 at a higher concentration (5 ⁇ M) are mixed with a target protein 1110 .
- the labeled ligand 1130 is known to react strongly with the target protein 1110 and is often the natural ligand.
- the receptor of the target protein 1110 is immobilized to the container and incubated with the mixture of labeled ligand and drug library compounds at step 1140 .
- the label on the ligand in this example is a molecule that fluoresces in a particular way when stimulated by light such as a laser or an ultraviolet light source. Radioactive compounds can also be used as labels.
- the free ligand is removed by washing at step 1155 and the amount of bound, labeled ligand is measured by detecting the amount and nature of the light emitted from the fluorescent label attached to ligand 1130 at step 1160 . If the fluorescence is reduced, then a reaction with a drug library compound has occurred, as shown at step 1180 . The reaction will reduce the amount of labeled ligand that reacts by a predicted amount ranging from 20% to 50% or more. If the fluorescence is not reduced, then a reaction has not occurred, as shown at step 1170 , since the labeled ligand reaction is not inhibited. The variation in the amount of fluorescent light for uninhibited binding is approximately 10%, resulting in an acceptable signal to noise ratio.
- the labeled ligand is incubated with the receptor and the drug library compounds but the receptor does not need to be immobilized.
- the assay relies on the observation that fluorescence from the labeled ligand bound to the receptor is substantially more polarized than the fluorescence from an unbound labeled ligand. Again in this approach, the signal produced is maximum when no the drug library compounds bind to the target receptor and is reduced by binding.
- reaction of the target protein and a labeled ligand is required for the assay.
- Lead profiling identifies and prioritizes a portfolio of compounds that have the best chance of success in clinical development.
- Assays can range from relatively simple ligand-receptor interaction to cell-based assays using genetically modified cells with multiple endpoints or reporter genes. The choice for a specific assay is determined by factors such as the desired target profile, sensitivity, robustness, and ease of automation.
- Drug leads are screened against other naturally occurring proteins to determine the level of interaction with these other targets. To become a drug lead, the protein must not only interact with the desired target but must not interact with other possibly similar proteins. Leads that do not affect proteins other than their target protein are more likely to not be toxic. Alternatively, a specific profile of interaction with more than one target may be desired, and specific other targets definitely excluded.
- FIG. 2 there is shown an embodiment of the nanocalorimeter as used for a lead profiling assay.
- a target substance to be screened for example a protein
- 1210 is combined at step 1220 with one or more drug library compounds 1230 , which had reacted with an original target protein.
- the drug lead is tested for reaction with other kinases as well as other key proteins to test activity level.
- the enthalpy of this reaction is measured at step 1240 .
- the enthalpy of this reaction is then compared with the enthalpy for a reaction with no inhibitor. If there is a reaction, it is identified at step 1260 ; if a reaction is not present, it is identified at step 1250 .
Abstract
Description
- This application is a continuation in part of U.S. application Ser. No. 10/114,611, filed Apr. 1, 2002, the disclosure of which is totally incorporated by reference.
- The following copending application, Attorney Docket Number D/A1578I1, U.S. application Ser. No. XX/XXXXX, filed Nov. 22, 2002, titled “Apparatus and Method for Multiple Target Assay for Drug Discovery”, is assigned to the same assignee of the present application. The entire disclosure of this copending application is totally incorporated herein by reference in its entirety.
- The following U.S. patents are fully incorporated herein by reference: U.S. Pat. No. 5,967,659 (“Ultrasensitive Differential Microcalorimeter with User-selected Gain Setting” to Plotnikov et al.); U.S. Pat. No. 6,079,873 (“Micron-scale Differential Scanning Calorimeter on a Chip” to Cavicchi et al.); U.S. Pat. No. 6,096,559 “Micromechanical Calorimetric Sensor” to Thundat et al.); and U.S. Pat. No. 6,193,413 (“System and Method for an Improved Calorimeter for Determining Thermodynamic Properties of Chemical and Biological Reactions” to Lieberman).
- This invention relates generally to a method for performing assays for drug discovery, and more specifically, to a method for performing lead drug profiling assays.
- In recent years, researchers and companies have turned to combinatorial methods and techniques for synthesizing, discovering and developing new compounds, materials, and chemistries. For example, pharmaceutical researchers have turned to combinatorial libraries as sources of new lead compounds for drug discovery. As another example, Symyx Technologies® is applying combinatorial techniques to materials discovery in the life sciences, chemical, and electronics industries. Consequently, there is a need for tools that can measure reactions and interactions of large numbers of small samples in parallel, consistent with the needs of combinatorial discovery techniques. Preferably, users desire that these tools enable inexpensive measurements and minimize contamination and cross-contamination problems. In addition there has been an explosion in the number of potential drug targets due to the accelerated implementation of genomics technologies and the completion of the Human Genome sequence.
- In some cases, the sample to be studied is precious, and it might not be acceptable to use the relatively large amount of material required by a standard microcalorimeter to perform only one measurement. For example, one may desire to study a natural extract or synthesized compound for biological interactions, but in some cases the available amount of material at concentrations large enough for calorimetry might be no more than a few milliliters. Performing a measurement in standard microcalorimeters, such as those sold, for example, by MicroCal® Inc. (model VP-ITC) or Calorimetry Sciences Corporation® (model CSC-4500), requires about1 ml of sample, which means that one would possibly be faced with using a majority or all of the precious material for one or a small series of measurements. Tools that enable calorimetric measurements with much smaller sample sizes would be helpful in overcoming this limitation.
- One of the most popular uses of combinatorial techniques to date has been in pharmaceutical research. Pharmaceutical researchers have turned to combinatorial libraries as sources of new lead compounds for drug discovery. A combinatorial library is a collection of chemical compounds which have been generated, by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” as reagents. For example, a combinatorial polypeptide library is formed by combining a set of amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can theoretically be synthesized through such combinatorial mixing of chemical building blocks.
- Once a library has been constructed, it must be screened to identify compounds, which possess some kind of biological or pharmacological activity. For example, screening can be done with a specific biological compound, often referred to as a target that participates in a known biological pathway or is involved in some regulatory function. The library compounds that are found to react with the targets are candidates for affecting the biological activity of the target, and hence a candidate for a therapeutic agent.
- Through the years, the pharmaceutical industry has increasingly relied on high throughput screening (HTS) of libraries of chemical compounds to find drug candidates. HTS describes a method where many discrete compounds are tested in parallel so that large numbers of test compounds are screened for biological activity simultaneously or nearly simultaneously. Currently, the most widely established techniques utilize 96-well microtitre plates. In this format, 96 independent tests are performed simultaneously on a single 8 cm×12 cm plastic plate that contains 96 reaction wells. These wells typically require assay volumes that range from 50 to 500 μl. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers and plate readers are commercially available to fit the 96-well format to a wide range of homogeneous and heterogeneous assays. To achieve faster testing, the industry is evolving to plates that contain 384 and 1536 wells.
- A variety of measurement approaches has been used to screen combinatorial libraries for lead compounds, one of which is the competitive binding assay. In this assay, a ligand, often the natural ligand in a biological pathway, is identified that will bind well with the target protein molecule. The assay often requires the chemical attachment of a fluorescent molecule to this marker ligand such that the fluorescent molecule does not affect the manner in which the marker ligand reacts with the target protein. Alternatively, the ligand could be radioactively labeled or labeled with a chemiluminescent molecule. To operate an inhibitor assay, the target protein is exposed to a mixture of the test ligands and marker ligands often in microtitre wells. After a time for reaction, the wells are rinsed such that free marker ligand is washed away. In wells where the target protein and the test ligand have reacted, the test ligand has blocked the active site of the target protein so the marker ligand cannot react and is washed away, while in cells where the target protein and test ligand have not reacted, the marker ligand has bound to the target protein and is not washed away. By investigating the wells for the presence of fluorescence after the washing, reactions of test ligands and target proteins can be determined as having occurred in wells where reduced fluorescence is observable relative to control wells to which no test ligands have been added.
- However, the competitive binding assay requires time and expense to develop the labeled reagents and assay. The principal components that need development are discovering a marker ligand and attaching a fluorophore to the marker in a manner that does not affect its reaction with the target protein. Attaching the fluorescent marker can often take 3 months of development or more and cost $250 k or more once the marker ligand is identified. An assay method that avoids such assay development, such as measuring the heat of the reaction with calorimetry, would eliminate this cost and time delay in the discovery process.
- The following disclosures may be relevant and/or helpful in providing an understanding of some aspect of the present invention:
- In Plotnikov et al., U.S. Pat. No. 5,967,659 (“Ultrasensitive Differential Microcalorimeter with User-selected Gain Setting”), a differential calorimeter is disclosed that includes sample and reference cells, a thermal shield surrounding the cells, heating devices thermally coupled to the thermal shield and the cells, a temperature monitoring system, and a control system. The temperature monitoring system monitors the temperature of the shield, cell temperatures, and temperature differentials between the cells and the shield. The control system generates output signals for control of the heating devices, with a gain setting and scan rate selected by means of a user interface. Output control signals are functions of input temperature signals and the user-selected gain setting, as well as functions of input temperature signals and the user-selected scan rate using a mapping function stored in memory.
- In Cavicchi et al., U.S. Pat. No. 6,079,873 (“Micron-scale Differential Scanning Calorimeter on a Chip”), a differential scanning microcalorimeter produced on a silicon chip enables microscopic scanning calorimetry measurements of small samples and thin films. The chip, fabricated using standard CMOS processes, includes a reference zone and a sample zone. The reference and sample zones may be at opposite ends of a suspended platform or may reside on separate platforms. Each zone is heated with an integrated polysilicon heater. A thermopile consisting of a succession of thermocouple junctions generates a voltage representing the temperature difference between the reference and sample zones.
- In Thundat et al., U.S. Pat. No. 6,096,559 (“Micromechanical Calorimetric Sensor”), a calorimeter sensor apparatus utilizes microcantilevered spring elements for detecting thermal changes within a sample containing biomolecules which undergo chemical and biochemical reactions. The spring element includes a bimaterial layer of chemicals on a coated region on at least one surface of the microcantilever. The chemicals generate a differential thermal stress across the surface upon reaction of the chemicals with an analyte or biomolecules within the sample due to the heat of chemical reactions in the sample placed on the coated region. The thermal stress across the spring element surface creates mechanical bending of the microcantilever. The spring element has a low thermal mass to allow detection and measuring of heat transfers associated with chemical and biochemical reactions within a sample place on or near the coated region. Deflections of the cantilever are detected by a variety of detection techniques.
- In Lieberman, U.S. Pat. No. 6,193,413 (“System and Method for an Improved Calorimeter for Determining Thermodynamic Properties of Chemical and Biological Reactions”) a microcalorimeter includes a thin amorphous membrane anchored to a frame within an environmental chamber. Thermometers and heaters are placed on one side of a thermal conduction layer mounted on the central portion of the membrane. Samples are placed on two such membranes; each sample is heated and its individual heat capacity determined. The samples are then mixed by sandwiching the two microcalorimeters together to cause a binding reaction to occur. The amount of heat liberated during the reaction is measured to determine the enthalpy of binding.
- Briefly stated, and in accordance with one aspect of the present invention, there is disclosed a method for performing drug lead profiling assays for drug discovery utilizing a nanocalorimeter. The method includes depositing not less than one drop containing a target solution to be screened and not less than one drop containing a drug library compound on a test substrate. After the drops are merged, a determination is made as to whether a reaction has occurred.
- The foregoing and other features of the instant invention will be apparent and easily understood from a further reading of the specification, claims and by reference to the accompanying drawings in which:
- FIG. 1 is a flow chart illustrating a prior art method for performing drug lead profiling; and
- FIG. 2 is an embodiment of the method for performing lead profiling assays in accordance with the present invention.
- As used herein, the term “ligand” refers to an agent that binds a target molecule. According to the present invention, a ligand is not limited to an agent that binds a recognized functional region of the target protein e.g. the active site of an enzyme, the antigen-combining site of an antibody, the hormone-binding site of a receptor, a cofactor-binding site, and the like. In practicing the present invention, a ligand can also be an agent that binds any surface or conformational domains of the target protein. Therefore, the ligands of the present invention encompass agents that in and of themselves may have no apparent or known biological function, beyond their ability to bind to the target protein in the manner described above.
- As used herein, the term “test ligand” refers to an agent, comprising a compound, molecule or complex, which is being tested for its ability to bind to a target molecule. Test ligands can be virtually any agent, including without limitation metals, peptides, proteins, lipids, polysaccharides, nucleic acids, small organic molecules, and combinations thereof. Complex mixtures of substances such as natural product extracts, which may include more than one test ligand, can also be tested, and the component that binds the target molecule can be purified from the mixture in a subsequent step.
- As used herein, the term “target protein” refers to a peptide, protein or protein complex for which identification of a ligand or binding partner is desired. Target proteins include without limitation peptides or proteins known or believed to be involved in the etiology of a given disease, condition or pathophysiological state, or in the regulation of physiological function. Target proteins may be derived from any living organism, such as a vertebrate, particularly a mammal and even more particularly a human. For use in the present invention, it is not necessary that the protein's biochemical function be specifically identified. Target proteins include without limitation receptors, enzymes, oncogene products, tumor suppressor gene products, vital proteins, and transcription factors, either in purified form or as part of a complex mixture of proteins and other compounds. Furthermore, target proteins may comprise wild type proteins, or, alternatively, mutant or variant proteins, including those with altered stability, activity, or other variant properties, or hybrid proteins to which foreign amino acid sequences, e.g. sequences that facilitate purification, have been added.
- As used herein, “test combination” refers to the combination of a test ligand and a target protein. “Control combination” refers to the target protein in the absence of a test ligand.
- As used herein, “screening” refers to the testing of a multiplicity of molecules or compounds for their ability to bind to a target molecule.
- As used herein, the term “lead molecule” refers to a molecule or compound, from a combinatorial library or other collection, which displays relatively high affinity for a target molecule. High affinity is detected by this invention through the heat released in a chemical reaction. The terms “lead compound” and “lead molecule” are synonymous.
- As used herein, the term “target molecule” encompasses peptides, proteins, nucleic-acids, protein-nucleic acid complexes and other receptors. The term encompasses both enzymes and proteins which are not enzymes. The term encompasses monomeric and multimeric proteins. Multimeric proteins may be homomeric or heteromeric. The term encompasses nucleic acids comprising at least two nucleotides, such as oligonucleotides. Nucleic acids can be single-stranded, double-stranded, or triple-stranded. The term encompasses a nucleic acid which is a synthetic oligonucleotide, a portion of a recombinant DNA molecule, or a portion of chromosomal DNA. The term target molecule also encompasses portions of peptides, secondary, tertiary, or quaternary structure through folding, with substituents including, but not limited to, cofactors, coenzymes, prosthetic groups, lipids, oligosaccharides, or phosphate groups.
- As used herein, the term “molecule” refers to the compound, which is tested for binding affinity for the target molecule. This term encompasses chemical compounds of any structure, including, but not limited to nucleic acids and peptides. More specifically, the term “molecule” encompasses compounds in a compound or a combinatorial library. The terms “molecule” and “ligand” are synonymous.
- As used herein, the term “thermal change” encompasses the release of energy in the form of heat or the absorption of energy in the form of heat.
- As used herein, the term “contacting a target molecule” refers broadly to placing the target molecule in solution with the molecule to be screened for binding. Less broadly, contacting refers to the turning, swirling, shaking or vibrating of a solution of the target molecule and the molecule to be screened for binding. More specifically, contacting refers to the mixing of the target molecule with the molecule to be tested for binding. Mixing can be accomplished, for example, by repeated uptake and discharge through a pipette tip or by deposition by robotic means. Preferably, contacting refers to the equilibration of binding between the target molecule and the molecule to be tested for binding.
- As used herein, the term “biochemical conditions” encompasses any component, thermodynamic property, or kinetic property of a physical, chemical, or biochemical reaction. Specifically, the term refers to conditions of temperature, pressure, protein concentration, pH, ionic strength, salt concentration, time, electric current, potential difference, and concentrations of cofactor, coenzyme, oxidizing agents, reducing agents, detergents, metal ion, ligands, buffer components, co-solvents including DMSO (dimethyl sulfoxide), glycerol, and related compounds, enhancers, and inhibitors.
- As used here in the term “lead profiling assay” encompasses the testing for reaction of a compound or a series of compounds with known binding activity towards a desired target against a plurality of other targets so as to determine a reactivity profile for said compound of compounds.
- The present invention encompasses nanocalorimeters and nanocalorimeter arrays that enable measurement of enthalpic changes, such as enthalpic changes arising from reactions, phase changes, changes in molecular conformation, and the like. Furthermore, the present invention encompasses combinatorial methods and high-throughput screening methods that use nanocalorimeters in the study, discovery, and development of new compounds, materials, chemistries, and chemical processes, as well as high-throughput monitoring of compounds or materials, or high-throughput monitoring of the processes used to synthesize or modify compounds or materials. The present invention also relates to compounds or materials identified by the above methods and their therapeutic uses (for diagnostic, preventive or treatment purposes), uses in purification and separation methods, and uses related to their novel physical or chemical properties. For the purposes herein, a nanocalorimeter refers to a device capable of measuring heats of reaction in the range of nanocalories.
- As an example, the present invention encompasses high-throughput screening methods for identifying a ligand that binds a target protein. If the target protein to which the test ligand binds is associated with or causative of a disease or condition, the ligand may be useful for diagnosing, preventing or treating the disease or condition. A ligand identified by the present method can also be one that is used in a purification or separation method, such as a method that results in purification or separation of the target protein from a mixture. The present invention also relates to ligands identified by the present method and their therapeutic uses (for diagnostic, preventive or treatment purposes) and uses in purification and separation methods.
- In practicing the present invention, the test ligand is combined with a target molecule, and the mixture is maintained under appropriate conditions and for a sufficient time to allow binding of the test ligand to the target molecule. Experimental conditions are determined empirically for each target molecule. When testing multiple test ligands, incubation conditions are usually chosen so that most ligand:target molecule interactions would be expected to proceed to completion. In high-throughput screening applications, the test ligand is usually present in molar excess relative to the target molecule. The target molecule can be in a soluble form, or, alternatively, can be bound to a solid phase matrix. The matrix may comprise without limitation beads, membrane filters, plastic surfaces, or other suitable solid supports.
- Binding to a given target is a prerequisite for pharmaceuticals intended to modify directly the action of that target. Thus, if a test ligand is shown, through use of the present method, to bind a target that reflects or affects the etiology of a condition, it may indicate the potential ability of the test ligand to alter target function and to be an effective pharmaceutical or lead compound for the development of such a pharmaceutical. Alternatively, the ligand may serve as the basis for the construction of hybrid compounds containing an additional component that has the potential to alter the target's function. For example, a known compound that inhibits the activity of a family of related enzymes may be rendered specific to one member of the family by conjugation of the known compound to a ligand, identified by the methods of the present invention, that binds specifically to that member at a different site than that recognized by the known compound.
- The fact that the present method is based on physicochemical properties common to most targets gives it widespread application. The present invention can be applied to large-scale systematic high-throughput procedures that allow a cost-effective screening of many thousands of test ligands. Once a ligand has been identified by the methods of the present invention, it can be further analyzed in more detail using known methods specific to the particular target used. Also, the ligand can be tested for its ability to influence, either positively or negatively, a known biological activity of the target.
- In the drug discovery process, a drug target protein is screened for reactivity against a large number (500,000) of compounds from a drug library of compounds. Often it is desirable to screen several different drug target proteins against the same library of proteins if the target proteins are thought to have a similar function such as the enzymatic function of a kinase.
- Turning to FIG. 1, there is shown an embodiment of a conventional drug screening process, a competitive screen, using a fluorescent assay. In a competitive screen, the reaction of the drug library compound with the target protein prevents the reaction of a second known reactive compound that contains a detectable label such as, in the case of a fluorescent assay, a fluorescent label. The level of reactivity of the drug library compound is inferred by detecting the fluorescence coming from the bound labeled compound. Several types of fluorescent assays are currently utilized in the art, but the two most practiced are fluorescence intensity and fluorescence polarization.
- In a fluorescence intensity assay, a labeled
ligand 1130 at a low concentration and one or moredrug library compounds 1150 at a higher concentration (5 μM) are mixed with atarget protein 1110. The labeledligand 1130 is known to react strongly with thetarget protein 1110 and is often the natural ligand. The receptor of thetarget protein 1110 is immobilized to the container and incubated with the mixture of labeled ligand and drug library compounds atstep 1140. The label on the ligand in this example is a molecule that fluoresces in a particular way when stimulated by light such as a laser or an ultraviolet light source. Radioactive compounds can also be used as labels. Following theincubation step 1152, the free ligand is removed by washing atstep 1155 and the amount of bound, labeled ligand is measured by detecting the amount and nature of the light emitted from the fluorescent label attached toligand 1130 atstep 1160. If the fluorescence is reduced, then a reaction with a drug library compound has occurred, as shown atstep 1180. The reaction will reduce the amount of labeled ligand that reacts by a predicted amount ranging from 20% to 50% or more. If the fluorescence is not reduced, then a reaction has not occurred, as shown atstep 1170, since the labeled ligand reaction is not inhibited. The variation in the amount of fluorescent light for uninhibited binding is approximately 10%, resulting in an acceptable signal to noise ratio. - For the fluorescence polarization approach, the labeled ligand is incubated with the receptor and the drug library compounds but the receptor does not need to be immobilized. Here the assay relies on the observation that fluorescence from the labeled ligand bound to the receptor is substantially more polarized than the fluorescence from an unbound labeled ligand. Again in this approach, the signal produced is maximum when no the drug library compounds bind to the target receptor and is reduced by binding. In both straight fluorescence and fluorescence polarization, reaction of the target protein and a labeled ligand is required for the assay.
- For competitive assays, a compound is required that strongly interacts with the protein target. This compound is often the ligand that reacts with the protein target in nature. In the fluorescent assays described here, this ligand must have an attached molecule that serves as a fluorescent label. The label must be attached in a manner that does not affect the ligand reaction to the protein target. Developing a competitive assay by creating such a labeled ligand is a costly, time-consuming effort.
- Lead profiling identifies and prioritizes a portfolio of compounds that have the best chance of success in clinical development. Assays can range from relatively simple ligand-receptor interaction to cell-based assays using genetically modified cells with multiple endpoints or reporter genes. The choice for a specific assay is determined by factors such as the desired target profile, sensitivity, robustness, and ease of automation. Drug leads are screened against other naturally occurring proteins to determine the level of interaction with these other targets. To become a drug lead, the protein must not only interact with the desired target but must not interact with other possibly similar proteins. Leads that do not affect proteins other than their target protein are more likely to not be toxic. Alternatively, a specific profile of interaction with more than one target may be desired, and specific other targets definitely excluded. Testing for interactions with these other proteins using existing technology requires a unique assay for each protein. In many cases, screening against other proteins can require many different assay formats and reagent development and consequently be costly and time-consuming. For competitive assays this requires a high affinity interaction between the protein and a labeled ligand.
- However, with the device taught herein, there is no need to develop a specific assay for each target, since a direct measurement of the heat of interaction is made utilizing calorimetry. Turning now to FIG. 2, there is shown an embodiment of the nanocalorimeter as used for a lead profiling assay. In FIG. 12, a target substance to be screened, for example a protein,1210 is combined at
step 1220 with one or moredrug library compounds 1230, which had reacted with an original target protein. For example, with a kinase inhibitor, the drug lead is tested for reaction with other kinases as well as other key proteins to test activity level. The enthalpy of this reaction is measured atstep 1240. The enthalpy of this reaction is then compared with the enthalpy for a reaction with no inhibitor. If there is a reaction, it is identified atstep 1260; if a reaction is not present, it is identified atstep 1250. - While the present invention has been illustrated and described with reference to specific embodiments, further modification and improvements will occur to those skilled in the art. It is to be understood, therefore, that this invention is not limited to the particular forms illustrated and that it is intended in the appended claims to embrace all alternatives, modifications, and variations which do not depart from the spirit and scope of this invention.
Claims (17)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/303,446 US20030186454A1 (en) | 2002-04-01 | 2002-11-22 | Apparatus and method for lead profiling assay |
US11/167,748 US7473031B2 (en) | 2002-04-01 | 2005-06-27 | Resistive thermal sensing |
US11/167,612 US7833800B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing with bridge circuitry |
US11/167,635 US7754492B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing device |
US11/167,746 US7473030B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/114,611 US7141210B2 (en) | 2002-04-01 | 2002-04-01 | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US10/303,446 US20030186454A1 (en) | 2002-04-01 | 2002-11-22 | Apparatus and method for lead profiling assay |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/114,611 Continuation-In-Part US7141210B2 (en) | 2002-04-01 | 2002-04-01 | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US10/303,500 Continuation-In-Part US7521253B2 (en) | 2002-04-01 | 2002-11-22 | Method for multiple target assay for drug discovery |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/114,611 Continuation-In-Part US7141210B2 (en) | 2002-04-01 | 2002-04-01 | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US11/167,748 Continuation-In-Part US7473031B2 (en) | 2002-04-01 | 2005-06-27 | Resistive thermal sensing |
US11/167,612 Continuation-In-Part US7833800B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing with bridge circuitry |
US11/167,746 Continuation-In-Part US7473030B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing |
US11/167,635 Continuation-In-Part US7754492B2 (en) | 2002-04-01 | 2005-06-27 | Thermal sensing device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030186454A1 true US20030186454A1 (en) | 2003-10-02 |
Family
ID=28041047
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/114,611 Expired - Lifetime US7141210B2 (en) | 2002-04-01 | 2002-04-01 | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US10/303,500 Expired - Lifetime US7521253B2 (en) | 2002-04-01 | 2002-11-22 | Method for multiple target assay for drug discovery |
US10/303,446 Abandoned US20030186454A1 (en) | 2002-04-01 | 2002-11-22 | Apparatus and method for lead profiling assay |
US11/149,632 Expired - Fee Related US7727768B2 (en) | 2002-04-01 | 2005-06-10 | Method for a nanocalorimeter for detecting chemical reactions |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/114,611 Expired - Lifetime US7141210B2 (en) | 2002-04-01 | 2002-04-01 | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US10/303,500 Expired - Lifetime US7521253B2 (en) | 2002-04-01 | 2002-11-22 | Method for multiple target assay for drug discovery |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/149,632 Expired - Fee Related US7727768B2 (en) | 2002-04-01 | 2005-06-10 | Method for a nanocalorimeter for detecting chemical reactions |
Country Status (3)
Country | Link |
---|---|
US (4) | US7141210B2 (en) |
EP (1) | EP1351052B1 (en) |
JP (1) | JP4290460B2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030183525A1 (en) * | 2002-04-01 | 2003-10-02 | Xerox Corporation | Apparatus and method for using electrostatic force to cause fluid movement |
US20050112766A1 (en) * | 2003-11-21 | 2005-05-26 | Palo Alto Research Center | Method for high-throughput screening assay sample preparation and analysis |
US20050112710A1 (en) * | 2003-11-21 | 2005-05-26 | Palo Alto Research Center Incorporated | Screening for ligand binding at specific target sites |
US20050238080A1 (en) * | 2002-04-01 | 2005-10-27 | Palo Alto Research Center Incorporated | Resistive thermal sensing |
US20050265898A1 (en) * | 2002-04-01 | 2005-12-01 | Palo Alto Research Center Incorporated | Thermal sensing |
US20060078999A1 (en) * | 2002-04-01 | 2006-04-13 | Palo Alto Research Center Incorporated | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US20060132542A1 (en) * | 2004-12-21 | 2006-06-22 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
EP2000796A2 (en) | 2007-06-08 | 2008-12-10 | Palo Alto Research Center Incorporated | Ranking fragment types with calorimetry |
US7473030B2 (en) | 2002-04-01 | 2009-01-06 | Palo Alto Research Center Incorporated | Thermal sensing |
US7833800B2 (en) | 2002-04-01 | 2010-11-16 | Palo Alto Research Center Incorporated | Thermal sensing with bridge circuitry |
US8168120B1 (en) | 2007-03-06 | 2012-05-01 | The Research Foundation Of State University Of New York | Reliable switch that is triggered by the detection of a specific gas or substance |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117376D0 (en) * | 2001-07-17 | 2001-09-05 | Amersham Pharm Biotech Uk Ltd | Thermocouple device |
US20040141541A1 (en) * | 2002-12-02 | 2004-07-22 | John Williams | MEMS-based thermogravimetric analyzer |
JP4762137B2 (en) * | 2003-04-28 | 2011-08-31 | アーマッド,ルブナ・エム | Thermoelectric biosensor for analysis in gas |
US20080053193A1 (en) * | 2003-04-28 | 2008-03-06 | Ahmad Lubna M | Thermoelectric sensor for analytes in a gas and related method |
US8722417B2 (en) | 2003-04-28 | 2014-05-13 | Invoy Technologies, L.L.C. | Thermoelectric sensor for analytes in a fluid and related method |
US20080053194A1 (en) * | 2003-04-28 | 2008-03-06 | Ahmad Lubna M | Thermoelectric sensor for analytes in a gas and related method |
US8088333B2 (en) * | 2003-04-28 | 2012-01-03 | Invoy Technology, LLC | Thermoelectric sensor for analytes in a gas |
US6989649B2 (en) * | 2003-07-09 | 2006-01-24 | A. O. Smith Corporation | Switch assembly, electric machine having the switch assembly, and method of controlling the same |
US8540493B2 (en) | 2003-12-08 | 2013-09-24 | Sta-Rite Industries, Llc | Pump control system and method |
US7553669B2 (en) * | 2003-12-18 | 2009-06-30 | Palo Alto Resaerch Center Incorporated | Osmotic reaction detector for monitoring biological and non-biological reactions |
US7615375B2 (en) * | 2003-12-18 | 2009-11-10 | Xerox Corporation | Osmotic reaction cell for monitoring biological and non-biological reactions |
US7413706B2 (en) * | 2003-12-19 | 2008-08-19 | Palo Alto Research Center Incorporated | Replaceable parylene membranes for nanocalorimeter |
US7745161B2 (en) * | 2003-12-19 | 2010-06-29 | Palo Alto Research Center Incorporated | Amplification of enzymatic reactions for use with an enthalpy array |
US7371006B2 (en) * | 2004-02-10 | 2008-05-13 | Perkinelmer Las, Inc. | Differential scanning calorimeter (DSC) with temperature controlled furnace |
WO2006073426A2 (en) * | 2004-04-20 | 2006-07-13 | California Institute Of Technology | Microscale calorimeters |
US6988826B2 (en) * | 2004-05-17 | 2006-01-24 | General Electric Company | Nano-calorimeter device and associated methods of fabrication and use |
US7874808B2 (en) | 2004-08-26 | 2011-01-25 | Pentair Water Pool And Spa, Inc. | Variable speed pumping system and method |
US8480373B2 (en) | 2004-08-26 | 2013-07-09 | Pentair Water Pool And Spa, Inc. | Filter loading |
US8043070B2 (en) | 2004-08-26 | 2011-10-25 | Pentair Water Pool And Spa, Inc. | Speed control |
US8469675B2 (en) | 2004-08-26 | 2013-06-25 | Pentair Water Pool And Spa, Inc. | Priming protection |
US7845913B2 (en) | 2004-08-26 | 2010-12-07 | Pentair Water Pool And Spa, Inc. | Flow control |
US8602745B2 (en) | 2004-08-26 | 2013-12-10 | Pentair Water Pool And Spa, Inc. | Anti-entrapment and anti-dead head function |
US7686589B2 (en) | 2004-08-26 | 2010-03-30 | Pentair Water Pool And Spa, Inc. | Pumping system with power optimization |
US8019479B2 (en) | 2004-08-26 | 2011-09-13 | Pentair Water Pool And Spa, Inc. | Control algorithm of variable speed pumping system |
US7790111B2 (en) * | 2004-12-20 | 2010-09-07 | Palo Alto Research Center Incorporated | Osmotic reaction detector for detecting biological and non-biological reactions |
US7914735B2 (en) * | 2005-01-18 | 2011-03-29 | Palo Alto Research Center Incorporated | Use of physical barriers to minimize evaporative heat losses |
US7695564B1 (en) * | 2005-02-03 | 2010-04-13 | Hrl Laboratories, Llc | Thermal management substrate |
US20070059213A1 (en) * | 2005-09-15 | 2007-03-15 | Lucent Technologies Inc. | Heat-induced transitions on a structured surface |
US7784173B2 (en) * | 2005-12-27 | 2010-08-31 | Palo Alto Research Center Incorporated | Producing layered structures using printing |
US8637138B2 (en) * | 2005-12-27 | 2014-01-28 | Palo Alto Research Center Incorporated | Layered structures on thin substrates |
US7816146B2 (en) * | 2005-12-27 | 2010-10-19 | Palo Alto Research Center Incorporated | Passive electronic devices |
EP2156171A4 (en) | 2007-05-16 | 2016-06-29 | Energetic Genomics Corp | A large array defferential scanning calorimeter, dsc measuring unit |
US8617899B2 (en) * | 2008-02-14 | 2013-12-31 | Palo Alto Research Center Incorporated | Enhanced drop mixing using magnetic actuation |
EP3418570B1 (en) | 2008-10-06 | 2020-01-22 | Pentair Water Pool and Spa, Inc. | Method of operating a safety vacuum release system |
DE102009014618A1 (en) * | 2009-03-24 | 2010-08-19 | Siemens Aktiengesellschaft | Heat conductivity detector for gas analyzer, has parylene layer that is formed in detector, and electrically heatable heater filaments that are mounted on center part of channel, where contact areas are releasable from parylene layer |
US8130072B2 (en) * | 2009-05-14 | 2012-03-06 | Palo Alto Research Center Incorporated | Vanadium oxide thermal microprobes |
US8393785B2 (en) * | 2009-05-14 | 2013-03-12 | Palo Alto Research Center Incorporated | Nanocalorimeter based on thermal probes |
US9556874B2 (en) | 2009-06-09 | 2017-01-31 | Pentair Flow Technologies, Llc | Method of controlling a pump and motor |
JP2011030208A (en) * | 2009-07-03 | 2011-02-10 | Panasonic Corp | Surface acoustic wave filter and duplexer using the same |
AU2011338297B2 (en) | 2010-12-08 | 2016-10-13 | Pentair Water Pool And Spa, Inc. | Discharge vacuum relief valve for safety vacuum release system |
EP2649196B1 (en) * | 2010-12-08 | 2015-03-18 | Imec | A biosensor using impedimetric real-time monitoring |
JP5976016B2 (en) * | 2011-02-22 | 2016-08-23 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Microdevices, methods for determining thermal properties of analytes, methods for measuring the amount of heat associated with a reaction |
JP5848020B2 (en) * | 2011-04-22 | 2016-01-27 | 特定非営利活動法人けいはんな文化学術協会 | Bioactivity measuring device |
FR2977034B1 (en) | 2011-06-21 | 2016-06-03 | Centre Nat Rech Scient | DIFFERENTIAL CALORIMETRIC MEASURING SENSOR AND METHOD FOR MANUFACTURING THE SAME |
ES2640280T3 (en) | 2011-11-01 | 2017-11-02 | Pentair Water Pool And Spa, Inc. | Flow blocking system and method |
JP5503675B2 (en) * | 2012-02-24 | 2014-05-28 | 一般財団法人カケンテストセンター | Sorption exothermic measuring device and measuring method |
US10168292B2 (en) * | 2012-03-22 | 2019-01-01 | California Institute Of Technology | Nanoscale calorimeter on chip and related methods and devices |
US9176012B2 (en) * | 2012-04-16 | 2015-11-03 | David Samuel Lieberman | Methods and systems for improved membrane based calorimeters |
JP5800336B2 (en) * | 2012-07-23 | 2015-10-28 | 株式会社リガク | Radiation measurement method and radiation measurement apparatus |
US9885360B2 (en) | 2012-10-25 | 2018-02-06 | Pentair Flow Technologies, Llc | Battery backup sump pump systems and methods |
EP2772753B1 (en) * | 2013-02-28 | 2018-10-03 | IMEC vzw | Heat-transfer resistance based analysis of bioparticles |
US10082500B2 (en) | 2013-08-22 | 2018-09-25 | Franz Baudenbacher | Device and method for detecting a target analyte |
US20150079583A1 (en) * | 2013-08-22 | 2015-03-19 | Vanderbilt University | Device and method for detecting a target analyte |
US9594039B2 (en) * | 2014-12-26 | 2017-03-14 | Palo Alto Research Center Incorporated | Photometric enthalpy change detection system and method |
US10139407B2 (en) | 2016-04-11 | 2018-11-27 | Universiteit Maastricht | Methods for detecting bacteria using polymer materials |
RU2607265C1 (en) * | 2015-11-17 | 2017-01-10 | Шлюмберже Текнолоджи Б.В. | Differential scanning calorimeter measurement cell |
US10324087B2 (en) | 2016-04-11 | 2019-06-18 | Universiteit Maastricht | Thermocouples comprising a polymer for detecting analytes and related methods |
US11835529B1 (en) | 2019-10-24 | 2023-12-05 | University Of Louisville Research Foundation, Inc. | Plasma thermograms for diagnosis and treatment of acute myocardial infarction |
WO2021081524A2 (en) * | 2019-10-24 | 2021-04-29 | The University Of Louisville Research Foundation, Inc. | Microfabricated differential scanning calorimetry system and methods of use thereof |
CN112415045B (en) * | 2020-10-19 | 2021-09-24 | 武汉大学 | Device and method for measuring material thermal adaptation coefficient under low air pressure |
CN113061023B (en) * | 2021-03-12 | 2023-05-09 | 兰州大学 | Preparation method of 3D printing ultra-light porous yttrium barium copper oxide high-temperature superconducting block |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5967659A (en) * | 1996-10-11 | 1999-10-19 | Microcal, Incorporated | Ultrasensitive differential microcalorimeter with user-selected gain setting |
US6079873A (en) * | 1997-10-20 | 2000-06-27 | The United States Of America As Represented By The Secretary Of Commerce | Micron-scale differential scanning calorimeter on a chip |
US6096559A (en) * | 1998-03-16 | 2000-08-01 | Lockheed Martin Energy Research Corporation | Micromechanical calorimetric sensor |
US6193413B1 (en) * | 1999-06-17 | 2001-02-27 | David S. Lieberman | System and method for an improved calorimeter for determining thermodynamic properties of chemical and biological reactions |
US6380605B1 (en) * | 1997-12-05 | 2002-04-30 | Imec Vzw | Device and a method for thermal sensing |
US6545334B2 (en) * | 1997-12-19 | 2003-04-08 | Imec Vzw | Device and a method for thermal sensing |
US20040038227A1 (en) * | 2000-05-08 | 2004-02-26 | Philippe Verwaerde | Method and technology for high-throughput lead profiling |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731340A (en) | 1987-02-24 | 1988-03-15 | Rockwell International Corporation | Dual lift-off self aligning process for making heterojunction bipolar transistors |
US5486337A (en) * | 1994-02-18 | 1996-01-23 | General Atomics | Device for electrostatic manipulation of droplets |
DE4423663A1 (en) * | 1994-07-06 | 1996-01-11 | Med Science Gmbh | Method and device for detecting thermal interactions between the human body and the device according to the invention and their correlation with the glucose concentration in human blood |
US5821598A (en) * | 1995-02-01 | 1998-10-13 | Research Corporation Technologies, Inc. | Uncooled amorphous YBaCuO thin film infrared detector |
JP3377162B2 (en) * | 1997-01-17 | 2003-02-17 | 株式会社リコー | Thermal analyzer and measurement method thereof |
FI980874A (en) * | 1998-04-20 | 1999-10-21 | Wallac Oy | Method and apparatus for conducting chemical analysis on small amounts of liquid |
US6402369B1 (en) | 1998-11-03 | 2002-06-11 | Sarnoff Corporation | Arrayable thermal assays |
US6436346B1 (en) * | 1999-09-14 | 2002-08-20 | U T Battelle, Llc | Micro-machined calorimetric biosensors |
DE19947788A1 (en) | 1999-10-05 | 2001-04-12 | Bayer Ag | Method and device for moving liquids |
JP2001264441A (en) * | 2000-01-14 | 2001-09-26 | Seiko Instruments Inc | Calorimeter and manufacturing method therefor |
US6488406B2 (en) * | 2000-03-23 | 2002-12-03 | Ta Instruments-Waters, Llc | Differential scanning calorimeter |
CA2421469A1 (en) * | 2000-09-05 | 2002-03-14 | The Althexis Company, Inc. | Drug discover employing calorimetric target triage |
US6843586B1 (en) | 2002-02-06 | 2005-01-18 | Thomas C. Allaire | Lighting assembly |
US7473030B2 (en) | 2002-04-01 | 2009-01-06 | Palo Alto Research Center Incorporated | Thermal sensing |
US7754492B2 (en) * | 2002-04-01 | 2010-07-13 | Palo Alto Research Center Incorporated | Thermal sensing device |
US7833800B2 (en) * | 2002-04-01 | 2010-11-16 | Palo Alto Research Center Incorporated | Thermal sensing with bridge circuitry |
US7141210B2 (en) | 2002-04-01 | 2006-11-28 | Palo Alto Research Center Incorporated | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US7147763B2 (en) * | 2002-04-01 | 2006-12-12 | Palo Alto Research Center Incorporated | Apparatus and method for using electrostatic force to cause fluid movement |
US7473031B2 (en) * | 2002-04-01 | 2009-01-06 | Palo Alto Research Center, Incorporated | Resistive thermal sensing |
US7416897B2 (en) * | 2003-11-21 | 2008-08-26 | Palo Alto Research Center Incorporated | Method for high-throughput screening assay sample preparation and analysis |
US7419835B2 (en) | 2003-11-21 | 2008-09-02 | Palo Alto Research Center Incorporated | Screening for ligand binding at specific target sites |
US7784173B2 (en) | 2005-12-27 | 2010-08-31 | Palo Alto Research Center Incorporated | Producing layered structures using printing |
US7816146B2 (en) | 2005-12-27 | 2010-10-19 | Palo Alto Research Center Incorporated | Passive electronic devices |
US8637138B2 (en) | 2005-12-27 | 2014-01-28 | Palo Alto Research Center Incorporated | Layered structures on thin substrates |
US7632008B2 (en) | 2007-06-08 | 2009-12-15 | Palo Alto Research Center Incorporated | Ranking fragment types with calorimetry |
-
2002
- 2002-04-01 US US10/114,611 patent/US7141210B2/en not_active Expired - Lifetime
- 2002-11-22 US US10/303,500 patent/US7521253B2/en not_active Expired - Lifetime
- 2002-11-22 US US10/303,446 patent/US20030186454A1/en not_active Abandoned
-
2003
- 2003-04-01 EP EP03007357A patent/EP1351052B1/en not_active Expired - Fee Related
- 2003-04-01 JP JP2003097637A patent/JP4290460B2/en not_active Expired - Lifetime
-
2005
- 2005-06-10 US US11/149,632 patent/US7727768B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5967659A (en) * | 1996-10-11 | 1999-10-19 | Microcal, Incorporated | Ultrasensitive differential microcalorimeter with user-selected gain setting |
US6079873A (en) * | 1997-10-20 | 2000-06-27 | The United States Of America As Represented By The Secretary Of Commerce | Micron-scale differential scanning calorimeter on a chip |
US6380605B1 (en) * | 1997-12-05 | 2002-04-30 | Imec Vzw | Device and a method for thermal sensing |
US6545334B2 (en) * | 1997-12-19 | 2003-04-08 | Imec Vzw | Device and a method for thermal sensing |
US20030152128A1 (en) * | 1997-12-19 | 2003-08-14 | Katarina Verhaegen | Device and a method for thermal sensing |
US6843596B2 (en) * | 1997-12-19 | 2005-01-18 | Vivactis Nv | Device and a method for thermal sensing |
US6096559A (en) * | 1998-03-16 | 2000-08-01 | Lockheed Martin Energy Research Corporation | Micromechanical calorimetric sensor |
US6193413B1 (en) * | 1999-06-17 | 2001-02-27 | David S. Lieberman | System and method for an improved calorimeter for determining thermodynamic properties of chemical and biological reactions |
US20040038227A1 (en) * | 2000-05-08 | 2004-02-26 | Philippe Verwaerde | Method and technology for high-throughput lead profiling |
US20040038228A1 (en) * | 2000-05-08 | 2004-02-26 | Katarina Verhaegen | Microphysiometer |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727768B2 (en) | 2002-04-01 | 2010-06-01 | Palo Alto Research Center Incorporated | Method for a nanocalorimeter for detecting chemical reactions |
US7754492B2 (en) | 2002-04-01 | 2010-07-13 | Palo Alto Research Center Incorporated | Thermal sensing device |
US7473031B2 (en) | 2002-04-01 | 2009-01-06 | Palo Alto Research Center, Incorporated | Resistive thermal sensing |
US7473030B2 (en) | 2002-04-01 | 2009-01-06 | Palo Alto Research Center Incorporated | Thermal sensing |
US20050265898A1 (en) * | 2002-04-01 | 2005-12-01 | Palo Alto Research Center Incorporated | Thermal sensing |
US20060078999A1 (en) * | 2002-04-01 | 2006-04-13 | Palo Alto Research Center Incorporated | Apparatus and method for a nanocalorimeter for detecting chemical reactions |
US7833800B2 (en) | 2002-04-01 | 2010-11-16 | Palo Alto Research Center Incorporated | Thermal sensing with bridge circuitry |
US20030183525A1 (en) * | 2002-04-01 | 2003-10-02 | Xerox Corporation | Apparatus and method for using electrostatic force to cause fluid movement |
US20050238080A1 (en) * | 2002-04-01 | 2005-10-27 | Palo Alto Research Center Incorporated | Resistive thermal sensing |
US20050112710A1 (en) * | 2003-11-21 | 2005-05-26 | Palo Alto Research Center Incorporated | Screening for ligand binding at specific target sites |
US20050112766A1 (en) * | 2003-11-21 | 2005-05-26 | Palo Alto Research Center | Method for high-throughput screening assay sample preparation and analysis |
EP1533609A3 (en) * | 2003-11-21 | 2012-05-23 | Palo Alto Research Center Incorporated | Screening for ligand binding at specific target sites, using a calorimetric device |
US8685216B2 (en) | 2004-12-21 | 2014-04-01 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
US20060132542A1 (en) * | 2004-12-21 | 2006-06-22 | Palo Alto Research Center Incorporated | Apparatus and method for improved electrostatic drop merging and mixing |
US8168120B1 (en) | 2007-03-06 | 2012-05-01 | The Research Foundation Of State University Of New York | Reliable switch that is triggered by the detection of a specific gas or substance |
US7632008B2 (en) | 2007-06-08 | 2009-12-15 | Palo Alto Research Center Incorporated | Ranking fragment types with calorimetry |
EP2000796A2 (en) | 2007-06-08 | 2008-12-10 | Palo Alto Research Center Incorporated | Ranking fragment types with calorimetry |
US20080304541A1 (en) * | 2007-06-08 | 2008-12-11 | Recht Michael I | Ranking Fragment Types with Calorimetry |
Also Published As
Publication number | Publication date |
---|---|
US20030186453A1 (en) | 2003-10-02 |
EP1351052A3 (en) | 2004-10-27 |
EP1351052A2 (en) | 2003-10-08 |
US20030186455A1 (en) | 2003-10-02 |
US7521253B2 (en) | 2009-04-21 |
US7727768B2 (en) | 2010-06-01 |
US20060078999A1 (en) | 2006-04-13 |
EP1351052B1 (en) | 2012-01-18 |
JP2003315292A (en) | 2003-11-06 |
JP4290460B2 (en) | 2009-07-08 |
US7141210B2 (en) | 2006-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7521253B2 (en) | Method for multiple target assay for drug discovery | |
AU759538B2 (en) | Continuous format high throughput screening | |
JP4405371B2 (en) | Screening for ligands that bind to specific target sites | |
Liu et al. | Technological advances in high-throughput screening | |
US6699655B2 (en) | Fluorescent polarization assays involving multivalent metal ions and systems | |
EP1281067B1 (en) | Method for high-throughput lead profiling | |
Lee et al. | Quantitative functional analysis of protein complexes on surfaces | |
WO2002099386A2 (en) | Microcalorimetric detection of analytes and binding events | |
US6713260B2 (en) | Methods of identifying compounds that bind to target species under isothermal denaturing conditions | |
EP1533608B1 (en) | Method for high-throughput screening with a calorimetric device | |
Venton et al. | Screening combinatorial libraries | |
EP1418239B1 (en) | Fluorescence assays for measuring enzyme activities involving polyions | |
AU2003231698B2 (en) | Fluorescence polarization assays involving polyions | |
AU5134300A (en) | Fluorescence polarization assays involving polyions | |
David et al. | SPR’s high impact on drug discovery | |
EP1701163A1 (en) | Fluorescence polarization assays involving polyions | |
AU2006202952A1 (en) | Fluorescence polarization assays involving polyions | |
JP2005534005A (en) | Ligand identification method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: XEROX CORPORATION, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUCE, RICHARD H.;ROSENBERG, STEVEN;REEL/FRAME:013554/0432;SIGNING DATES FROM 20021119 TO 20021120 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, AS COLLATERAL AGENT, TEXAS Free format text: SECURITY AGREEMENT;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:015134/0476 Effective date: 20030625 Owner name: JPMORGAN CHASE BANK, AS COLLATERAL AGENT,TEXAS Free format text: SECURITY AGREEMENT;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:015134/0476 Effective date: 20030625 |
|
AS | Assignment |
Owner name: PALO ALTO RESEARCH CENTER, INCORPORATED, CALIFORNI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:XEROX CORPORATION;REEL/FRAME:014940/0724 Effective date: 20040116 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: XEROX CORPORATION, CONNECTICUT Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A. AS SUCCESSOR-IN-INTEREST ADMINISTRATIVE AGENT AND COLLATERAL AGENT TO JPMORGAN CHASE BANK;REEL/FRAME:066728/0193 Effective date: 20220822 |